PS-BPC05-9: MYELOPEROXIDASE PROGNOSTIC ROLE IN HYPERTENSIVE PATIENTS AFTER MYOCARDIAL INFARCTION WITH ST-ELEVATION

Abstract

Objectives: The aim was to study the role of myeloperoxidase (MPO) in left ventricle hypertrophy prognosis in hypertensive patients with ST-elevation myocardial infarction (STEMI) within 12 months. Design and Methods: Patients were divided into two groups depending on the level of MPO (median 95.68 ng / ml). Group 1 (with MPO> 95.68 ng/ml) included 48 patients. Group 2 with MPO < 95.68 ng/ml included 48 patients. The level of MPO was determined in all patients on the first day of the disease by enzyme-linked immunosorbent assay using a set of reagents Human MPO Instant ELISA KIT, Invitrogen Austria. The endpoint included left ventricle hypertrophy onset/progression, and was assessed after 12 months of follow up. Results: In the analysis of the two groups, it was found that patients in group 2 had significantly higher MPO 159.17 IQR 97.81 to 189.23 compared with the first group 65.77 IQR 48.18 to 94.23 p = 0.039. In univariative logistic analyses MPO showed significant association with LV hypertrophy development, β; = 0.033;p < 0.001. Multivariate logistic analysis revealed the reverse correlation of MPO with the LV remodeling in 12 months follow up β; = 0.010; p = 0.0034. Conclusion: The increased level of MPO is a significant predictor for development of left ventricle hypertrophy in hypertensive patients after STEMI in 12 month follow up